SOPHiA GENETICS Unveils AI-Driven Patient Stratification Research at ESMO 2024

SOPHiA GENETICS, a prominent healthcare technology firm specializing in data-driven medicine, is set to present groundbreaking research at the upcoming European Society for Medical Oncology (ESMO) 2024 conference. This study, conducted in collaboration with AstraZeneca, employs advanced artificial intelligence techniques to identify specific subgroups of stage IV non-small cell lung cancer (NSCLC) patients who are likely to benefit most from a combination treatment involving tremelimumab, durvalumab, and chemotherapy.

The core of this research is a retrospective, multimodal analysis of data derived from the POSEIDON Phase 3 clinical trial (NCT03164616). This trial had previously established that the combination of tremelimumab, durvalumab, and chemotherapy significantly enhances progression-free survival (PFS) and overall survival (OS) in patients with metastatic NSCLC, leading to the global approval of this treatment regimen for first-line metastatic NSCLC (1L mNSCLC). Utilizing sophisticated multimodal machine learning models, SOPHiA GENETICS analyzed an array of clinical, biological, genomic, and imaging data to identify patient subgroups most likely to benefit from this combination therapy.

One of the pivotal outcomes of the study was the identification of certain biological signatures. Specifically, patients with non-squamous metastatic NSCLC who were EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, had KRAS mutations, or STK11 mutations were found to experience a higher OS benefit from the addition of tremelimumab to durvalumab and chemotherapy. These findings could potentially revolutionize NSCLC treatment by paving the way for more personalized therapy options.

Jurgi Camblong, Ph.D., Co-founder and CEO of SOPHiA GENETICS, emphasized the significance of this collaboration with AstraZeneca in advancing personalized oncology. "Non-small cell lung cancer remains one of the most challenging cancers to treat due to its complex biology and the advanced stage at which it is often diagnosed," Camblong noted. He highlighted that the study leverages multimodal data and advanced AI to tailor treatment strategies to individual patients, thereby improving outcomes and offering new hope for those affected by this aggressive disease.

Ferdinandos Skoulidis from the Department of Thoracic Medical Oncology at the University of Texas MD Anderson Cancer Center will present the study as a poster at ESMO 2024 in Barcelona, Spain, scheduled from September 13-17, 2024. His presentation will focus on the feasibility and clinical impact of large-scale multimodal analyses in oncology.

SOPHiA GENETICS is recognized for its cloud-native healthcare technology platform, SOPHiA DDM™, which analyzes complex genomic and multimodal data to generate actionable insights. The company is committed to expanding access to data-driven medicine, particularly for patients with cancer and rare disorders, across a global network of hospitals, laboratories, and biopharma institutions.

This new research underscores the potential of using multimodal machine learning to enhance the precision of treatment for NSCLC patients, marking a significant milestone in the field of personalized medicine. By identifying those patients most likely to benefit from specific therapies, SOPHiA GENETICS aims to improve treatment outcomes and offer new avenues of hope for patients battling this challenging disease.